Anti-inflammatory compounds
View Patent ↗This invention relates to novel compounds obtained by fermentation of Myxobacteria strain (PM0670013/MTCC 5570). The present invention further relates to the processes for the production of the novel anti-inflammatory compounds, to the culture no. PM0670013 (MTCC 5570), and to pharmaceutical compositions containing compounds of the present invention as an active ingredient and its use in medicines for the treatment of inflammatory diseases or disorders mediated by proinflammatory cytokines such as Tumor Necrosis Factor-alpha (TNF-α) and/or interleukins such as IL-6, having anti-inflammatory activity The invention also includes all stereoisomeric forms of compounds of the present invention.
1. A compound selected from the group consisting of the compound of formula I and the compound of formula II,
or a stereoisomer thereof.
2. The compound according to claim 1 of formula I;
or a stereoisomer thereof.
3. The compound of formula I, or a stereoisomer thereof, according to claim 2 , wherein
(a) molecular weight is 255.15,
(b) molecular formula is C 13 H 21 NO 4 ,
(c) 1 H NMR spectrum (500 MHz, CDCl 3 ) is: δ 4.1 (t, 6.5 Hz, 2H), 3.5 (m, 2H), 3.46 (m, 1H), 2.82 (t, 8 Hz, 2H), 2.62 (t, 8 Hz, 2H), 1.75 (m, 2H), 1.64 (t, 6.5 Hz, 2H), 1.4 (m, 1H), 1.35 (m, 2H), 1.31 (m, 2H), 0.9 (t, 6.5 Hz, 3H) (as depicted in FIG. 1 ),
(d) 13 C NMR spectrum (75 MHz, CDCl 3 ) is: δ 168.8 (2C), 67.43, 64.80, 54.00, 32.27, 29.60, 28.50, 26.55, 26.00, 23.20, 23.04, 14.01, and
(e) IR (KBr) spectrum is 2924, 2853, 1735, 1670, 1466, 1375 cm −1 .
4. The compound of Formula II according to claim 1 ;
or a stereoisomer thereof.
5. The compound of formula II, or a stereoisomer thereof, according to claim 4 , wherein
(a) molecular weight is 244.36,
(b) molecular formula is C 13 H 28 N 2 O 2 ,
(c) 1 H NMR spectrum (500 MHz, CDCl 3 ) is: δ 3.54 (t, 8.5 Hz, 2H), 3.45 (s, 3H), 1.75 (m, 2H), 1.39 (m, 2H), 1.29 (s, 4H), 1.26 (s, 12H), 0.88 (t, 7 Hz, 3H) (as depicted in FIG. 2 );
(d) 13 C NMR spectrum (75 MHz, CDCl 3 ) is: δ 67.07, 53.40, 31.90, 29.67, 29.64, 29.58, 29.46, 29.36, 29.23, 26.2, 23.2, 22.70, 14.10, and
(e) IR (KBr) spectrum is 3378, 3016, 2918, 2850, 1663, 1463, 1235, 950, 729 cm −1 .
6. A process for the production of the compound of formula I and compound of formula II as defined in claim 1 , comprising the steps of:
(a) cultivating the culture no. PM0670013 (MTCC 5570) or one of its variants or mutants by fermentation, under submerged aerobic conditions in a nutrient medium containing sources of carbon, nitrogen and inorganic salts to produce the compound of formula I and compound of formula II,
(b) isolating the compound of formula I and compound of formula II by extraction or fractionation using a solvent from the fermented broth, and
(c) purifying the compound of formula I and the compound of formula II.
7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of formula I or the compound of formula II according to claim 1 or a stereoisomer thereof; and a pharmaceutically acceptable carrier or diluent.
8. A method for the treatment of an inflammatory disorder mediated by tumor necrosis factor-α (TNF-α) or interleukin-6 (IL-6) or a combination thereof, comprising administering to a mammal in need thereof a therapeutically effective amount of the compound of formula I or the compound of formula II according to claim 1 or a stereoisomer thereof, wherein the inflammatory disorder mediated by TNF-α or IL-6 is selected from the group consisting of inflammatory bowel disease, inflammation, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, osteoarthritis, refractory rheumatoid arthritis, chronic non-rheumatoid arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, psoriasis and systemic lupus erythematosus.